Associated Papers
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R et al.
Science Advances, 2024
38536921 (PubMed )
Supplement: sciadv.adm9859_sm.pdf
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK et al.
Npj Precision Oncology, 2022
36494601 (PubMed )
Supplement: 41698_2022_334_MOESM1_ESM.pdf
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Mutation profile of non-small cell lung cancer revealed by next generation sequencing.
Chang YS et al.
Respiratory Research, 2021
Rare and common genetic variations in the Keap1/Nrf2 antioxidant response pathway impact thyroglobulin gene expression and circulating levels, respectively.
Matana A et al.
Biochemical Pharmacology, 2020
Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F et al.
Cancer Medicine, 2019
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Aredo JV et al.
Lung Cancer (amsterdam, Netherlands), 2019
Select a paper to view details